Related Experiment Video

Updated: Jun 21, 2026

Automated Preparation of [68Ga]Ga-3BP-3940 on a Synthesis Module for PET Imaging of the Tumor Microenvironment
10:33

Automated Preparation of [68Ga]Ga-3BP-3940 on a Synthesis Module for PET Imaging of the Tumor Microenvironment

Published on: April 25, 2025

Rilotumumab, a mAb against human hepatocyte growth factor for the treatment of cancer

Silvia Giordano1

  • 1University of Torino Medical School, Institute for Cancer Research and Treatment (IRCC), Torino, Italy. silvia.giordano@ircc.it

Current Opinion in Molecular Therapeutics
|August 4, 2009
PubMed

Insights

Rilotumumab, an antibody targeting hepatocyte growth factor (HGF), inhibits cancer cell growth by blocking the HGF-c-Met pathway. Clinical trials show it is well-tolerated and effective when combined with chemotherapy.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Tyrosine kinase receptors and ligands are key targets in cancer therapy.
  • Hepatocyte growth factor (HGF) and its receptor c-Met drive tumor proliferation, invasion, and apoptosis resistance.
  • Aberrant HGF/c-Met signaling is implicated in various human cancers.

Purpose of the Study:

  • To evaluate the efficacy and safety of rilotumumab, a humanized monoclonal antibody targeting HGF.
  • To investigate the potential of rilotumumab in blocking HGF-c-Met interactions and downstream signaling.
  • To assess the additive effects of rilotumumab in combination with chemotherapy.

Main Methods:

  • Preclinical studies involving in vitro assays to assess c-Met phosphorylation inhibition.
  • Phase I clinical trials to evaluate safety and tolerability of rilotumumab.
  • Phase Ib trials examining combination therapy with chemotherapeutic agents.

Main Results:

  • Rilotumumab effectively inhibited c-Met phosphorylation and downstream signaling in preclinical models.
  • Phase I trials demonstrated rilotumumab was well-tolerated at tested doses.
  • Preclinical and Phase Ib data indicated an additive effect when rilotumumab was combined with chemotherapy.

Conclusions:

  • Rilotumumab demonstrates potential as a targeted cancer therapeutic by inhibiting the HGF/c-Met pathway.
  • Combination therapy with rilotumumab and chemotherapy shows promise for enhanced anti-tumor activity.
  • Further Phase II trials are ongoing to determine optimal tumor types and patient selection for rilotumumab treatment.

More Related Videos

A Simple Guide Screw Method for Intracranial Xenograft Studies in Mice08:11

A Simple Guide Screw Method for Intracranial Xenograft Studies in Mice

Published on: September 26, 2011

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...